Nanodelivery of a multimodal drug Cerebrolysin reduces brain pathology following amyloid beta peptide infusion induced Alzheimer’s disease
during a critical therapeutic time window is able to attenuate AD pathology, and (ii) nanodelivery of cerebrolysin has superior effects and extended therapeutic window in AD. The possible mechanisms

